A midtown Manhattan high-rise undergoing an office-to-apartment conversion experienced buckled interior columns and sagging floors on Tuesday, triggering mass evacuations. While roads and nearby buildings have partially reopened, New York City Mayor Zohran Mamdani has promised a full investigation into the structural breakdown at the former Pfizer headquarters. What caused the structural damage in the … Read more
City officials declared a Midtown Manhattan building “stable” late Tuesday, following an emergency evacuation triggered by buckling structural columns. While the Department of Buildings continues to monitor the site, traffic remains restricted on East 42nd and 43rd Streets between Second and Third Avenues, and five neighboring buildings remain partially or fully evacuated as of Wednesday … Read more
Novo Nordisk (NVO) and Pfizer (PFE) stand out as the cheapest large-cap healthcare names in 2026, trading at forward price-to-earnings multiples of 14x and 8x, respectively. Both companies currently grapple with significant headwinds—including drug pricing reforms and patent cliffs—but maintain strong free cash flow and upcoming data catalysts, according to data from 24/7 Wall St. … Read more
Colorado has secured federal authorization to import lower-cost prescription drugs from Canada, a move state officials estimate could save residents approximately $46 million on 20 common medications over three years. However, the program faces significant logistical hurdles, including Canadian export restrictions and private manufacturing contracts that currently prevent the sale of these drugs to the … Read more
The Trillion-Dollar Shift: Navigating the Future of Healthcare Investing The economic landscape of healthcare is undergoing a seismic shift. According to the Committee for a Responsible Federal Budget, federal healthcare spending is projected to climb from less than $2 trillion today to more than $3 trillion within a decade. View this post on Instagram about … Read more
A New Weapon in the Fight Against Lyme Disease: Pfizer and Valneva’s Promising Vaccine For the first time in decades, a potential Lyme disease vaccine is on the horizon. Pharmaceutical giants Pfizer and Valneva announced Monday that their vaccine candidate, PF-07307405 (formerly known as VLA15), has demonstrated over 70% efficacy in preventing Lyme disease in … Read more
Lyme Disease Vaccine Breakthrough: Pfizer and Valneva Report Promising Results A new Lyme disease vaccine candidate has demonstrated strong efficacy in a clinical trial, paving the way for potential market authorization. Pharmaceutical companies Pfizer and Valneva announced the positive results on Monday, March 23, 2026, offering a potential new defense against this debilitating bacterial infection. … Read more
Trump’s Drug Pricing Deals: A Three-Year Window for Change? President Trump’s push for lower prescription drug prices, often touted through “most-favored nation” (MFN) deals with pharmaceutical companies, continues to be a subject of scrutiny. Recent Securities and Exchange Commission (SEC) filings reveal a key detail previously undisclosed: at least some of these agreements are set … Read more
BioNTech Sues Moderna: A Deep Dive into the mRNA Patent Wars German pharmaceutical company BioNTech has initiated legal proceedings against Moderna in the United States, alleging patent infringement related to its mRNA vaccine technology. The lawsuit, filed in Delaware federal court, centers around Moderna’s new COVID-19 vaccine, mNexspike, which BioNTech claims violates patents used in … Read more
The Shifting Sands of the Weight-Loss Market: Opportunities Beyond the GLP-1 Hype Even as Eli Lilly (NYSE: LLY) currently dominates investor attention with its blockbuster GLP-1 drugs, Mounjaro and Zepbound, a closer look reveals potential opportunities in the stocks of its competitors, Novo Nordisk (NYSE: NVO) and Pfizer (NYSE: PFE). The market isn’t a one-horse … Read more